[go: up one dir, main page]

WO2010013495A1 - Composition pharmaceutique contenant un agent thérapeutique à base de neurotoxine botulinique en tant que principe actif, et son utilisation - Google Patents

Composition pharmaceutique contenant un agent thérapeutique à base de neurotoxine botulinique en tant que principe actif, et son utilisation Download PDF

Info

Publication number
WO2010013495A1
WO2010013495A1 PCT/JP2009/003664 JP2009003664W WO2010013495A1 WO 2010013495 A1 WO2010013495 A1 WO 2010013495A1 JP 2009003664 W JP2009003664 W JP 2009003664W WO 2010013495 A1 WO2010013495 A1 WO 2010013495A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
highly purified
active ingredient
purified botulinum
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2009/003664
Other languages
English (en)
Japanese (ja)
Inventor
赤池紀生
加藤啓子
原川哲博
銀永明弘
奥田祥士
大山裕介
永野礼隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Kumamoto Health Science University
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Kumamoto Health Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Kumamoto Health Science University filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Priority to JP2010522632A priority Critical patent/JPWO2010013495A1/ja
Publication of WO2010013495A1 publication Critical patent/WO2010013495A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un agent thérapeutique pour des maladies du système nerveux central et périphérique. L’agent thérapeutique comporte, en tant que principe actif, une toxine botulinique hautement purifiée dérivée de Clostridium botulinum incapable de produire une protéine HA et ayant un poids moléculaire de 150 kDa. L’agent thérapeutique est un neuromodulateur capable de moduler le type ou la quantité d’un neuro-transmetteur, qui est une substance agissant principalement dans un réseau neuronal, lorsque la toxine botulinique hautement purifiée est administrée directement à un nerf central ou un nerf périphérique chez un patient souffrant d’une maladie du système nerveux central et périphérique.
PCT/JP2009/003664 2008-07-31 2009-07-31 Composition pharmaceutique contenant un agent thérapeutique à base de neurotoxine botulinique en tant que principe actif, et son utilisation Ceased WO2010013495A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010522632A JPWO2010013495A1 (ja) 2008-07-31 2009-07-31 高度精製ボツリヌス毒素治療剤を有効成分として含有する薬学的組成物およびその利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008199069 2008-07-31
JP2008-199069 2008-07-31

Publications (1)

Publication Number Publication Date
WO2010013495A1 true WO2010013495A1 (fr) 2010-02-04

Family

ID=41610205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/003664 Ceased WO2010013495A1 (fr) 2008-07-31 2009-07-31 Composition pharmaceutique contenant un agent thérapeutique à base de neurotoxine botulinique en tant que principe actif, et son utilisation

Country Status (2)

Country Link
JP (1) JPWO2010013495A1 (fr)
WO (1) WO2010013495A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069609A (zh) * 2015-12-11 2018-12-21 雷文斯治疗公司 使用神经递质的用于原发性情绪和情感障碍的肉毒杆菌毒素
US10960060B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
WO2021077055A1 (fr) * 2019-10-18 2021-04-22 Penland Foundation Toxine botulique destinée à être utilisée dans un traitement
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
US11090371B1 (en) 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
US11738071B2 (en) 2021-07-12 2023-08-29 Penland Foundation Treatment of acute and chronic kidney disease
US11925677B2 (en) 2021-07-12 2024-03-12 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
JP2024522931A (ja) * 2021-07-08 2024-06-21 ファルマ リサーチ バイオ シーオー・，エルティーディー． 非毒素タンパク質が除去されたクロストリジウム・ボツリヌス神経毒素タンパク質の精製方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004503504A (ja) * 2000-06-14 2004-02-05 アラーガン、インコーポレイテッド 運動障害の処置法
JP2005530770A (ja) * 2002-05-10 2005-10-13 アラーガン、インコーポレイテッド ボツリヌス毒素のようなクロストリジウム神経毒による、神経精神医学的障害の頭蓋内処置
JP2007509953A (ja) * 2003-10-29 2007-04-19 アラーガン、インコーポレイテッド 神経障害および神経精神障害のボツリヌス毒素処置
WO2008050866A1 (fr) * 2006-10-27 2008-05-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Préparation contenant une toxine botulinique de type a hautement purifiée issue d'un pathogène du botulisme chez l'enfant
JP2009132672A (ja) * 2007-10-31 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチドを有効成分として含む鎮痛作用を有する医薬組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004503504A (ja) * 2000-06-14 2004-02-05 アラーガン、インコーポレイテッド 運動障害の処置法
JP2005530770A (ja) * 2002-05-10 2005-10-13 アラーガン、インコーポレイテッド ボツリヌス毒素のようなクロストリジウム神経毒による、神経精神医学的障害の頭蓋内処置
JP2007509953A (ja) * 2003-10-29 2007-04-19 アラーガン、インコーポレイテッド 神経障害および神経精神障害のボツリヌス毒素処置
WO2008050866A1 (fr) * 2006-10-27 2008-05-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Préparation contenant une toxine botulinique de type a hautement purifiée issue d'un pathogène du botulisme chez l'enfant
JP2009132672A (ja) * 2007-10-31 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチドを有効成分として含む鎮痛作用を有する医薬組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KEIJI OGUMA: "Botulinus Dokuso no Idenshi Oyobi Kozo to Kino ni Kansuru Kenkyu", JAPANESE JOURNAL OF BACTERIOLOGY, vol. 60, no. 4, 2005, pages 521 - 530 *
MITSUHIKO YOKOYAMA ET AL.: "Kairyogata Botulinus Dokuso o Mochiita Translational Research", THE NISHINIHON JOURNAL OF UROLOGY, vol. 68, no. 6, 2006, pages 234 - 238 *
RYUJI KAJI: "Botulinus Dokuso Chiryo no Kongo no Tenbo", THE JOURNAL OF THE JAPANESE SOCIETY OF INTERNAL MEDICINE, vol. 95, no. 9, 2006, pages 1895 - 1899 *
TOYOHIKO WATANABE ET AL.: "Hinyokika no Saizensen Shitteokitai Hinyokika no Atarashii Chiryo to Care no Yoten Kakatsudo Boko (OAB) ni Taisuru Chiryo no Saizensen Botulinus Dokuso Bokohekinai Chunyu Ryoho", UROLOGICAL NURSING, vol. 13, no. 7, 10 July 2008 (2008-07-10), pages 693 - 695 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069609A (zh) * 2015-12-11 2018-12-21 雷文斯治疗公司 使用神经递质的用于原发性情绪和情感障碍的肉毒杆菌毒素
JP2019504824A (ja) * 2015-12-11 2019-02-21 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 神経伝達物質の使用による原発性の気分及び感情障害のためのボツリヌス毒素
AU2020365148B2 (en) * 2019-10-18 2022-10-27 Penland Foundation Botulinum toxin for use in treatment
AU2022202689B2 (en) * 2019-10-18 2022-12-01 Penland Foundation Botulinum toxin for use in treatment
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
WO2021077055A1 (fr) * 2019-10-18 2021-04-22 Penland Foundation Toxine botulique destinée à être utilisée dans un traitement
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
US11090371B1 (en) 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
US11439694B2 (en) 2019-10-18 2022-09-13 Penland Foundation Botulinum toxin for use in treatment of autism spectrum disorders
EP4045073A4 (fr) * 2019-10-18 2022-12-07 Penland Foundation Toxine botulique destinée à être utilisée dans un traitement
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10960060B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
JP2022543925A (ja) * 2019-10-18 2022-10-14 ペンランド ファウンデーション 治療に使用するためのボツリヌス毒素
JP2023116752A (ja) * 2019-10-18 2023-08-22 ペンランド ファウンデーション 治療に使用するためのボツリヌス毒素
JP7706178B2 (ja) 2019-10-18 2025-07-11 ペンランド ファウンデーション 治療に使用するためのボツリヌス毒素
US11744881B2 (en) 2019-10-18 2023-09-05 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US11883473B2 (en) 2019-10-18 2024-01-30 Penland Foundation Treatment of dyslexia using botulinum toxin
US12251431B2 (en) 2019-10-18 2025-03-18 Penland Foundation Botulinum toxin for use in treatment of autism spectrum disorders
JP2024522931A (ja) * 2021-07-08 2024-06-21 ファルマ リサーチ バイオ シーオー・，エルティーディー． 非毒素タンパク質が除去されたクロストリジウム・ボツリヌス神経毒素タンパク質の精製方法
JP7680099B2 (ja) 2021-07-08 2025-05-20 ファルマ リサーチ バイオ シーオー・，エルティーディー． 非毒素タンパク質が除去されたクロストリジウム・ボツリヌス神経毒素タンパク質の精製方法
US11925677B2 (en) 2021-07-12 2024-03-12 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
US11738071B2 (en) 2021-07-12 2023-08-29 Penland Foundation Treatment of acute and chronic kidney disease

Also Published As

Publication number Publication date
JPWO2010013495A1 (ja) 2012-01-05

Similar Documents

Publication Publication Date Title
WO2010013495A1 (fr) Composition pharmaceutique contenant un agent thérapeutique à base de neurotoxine botulinique en tant que principe actif, et son utilisation
AU2018253620A1 (en) Injectable botulinum toxin formulations
WO2007062078A3 (fr) Composes modulant l'activite thrombopoietine et procedes correspondants
WO2011154126A3 (fr) Traitement antivieillissement pour la peau
WO2007002516A3 (fr) Formes de dosage ameliorees pour le traitement de troubles moteurs
WO2004105702A3 (fr) Compositions pharmaceutiques expansibles et procedes de traitement d'un trouble donne
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
BR112014009851A2 (pt) moduladores de receptor de nmda e usos dos mesmos
BRPI0509863A (pt) liberação de fármaco para fundo de olho
WO2011119227A3 (fr) Compositions pour le traitement de troubles du système nerveux central comprenant la dépression utilisant une nouvelle thérapie d'association de médicaments pour réduire la suicidabilité chez des patients
WO2008036682A3 (fr) Traitement des troubles hépatiques par l'administration de conjugués de protéine associée au récepteur (rap)
WO2006035237A3 (fr) Procedes et compositions lies a la maladie d'alzheimer
EP2322219A3 (fr) Utilisation des antagonistes IL-23 et IL-17 pour traiter la maladie inflammatoire oculaire auto-immune
WO2006082588A3 (fr) Procede et dispositif d'administration ophtalmique d'ingredients pharmaceutiquement actifs
WO2007066149A3 (fr) Compositions pharmaceutiques topiques
WO2007100366A3 (fr) Modulateurs allostériques positifs du récepteur de la quinolone m1
WO2008060515A3 (fr) Compositions topiques comprenant des acides et/ou des lactones polyhydroxy permettant d'améliorer les effets cutanés de médicaments thérapeutiques oxydants
WO2006039704A3 (fr) Composition pharmaceutique et methode de traitement d'une arthropathie a capsule articulaire
BR112012006010A2 (pt) composto de glicina
WO2008022345A3 (fr) Compositions et procédés pour inhiber le cytochrome p450
MX2007004765A (es) Compuestos y metodos que modulan la actividad de la trombopoyetina.
NZ602479A (en) Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
Zhong et al. Blockade of N-acetylaspartylglutamate peptidases: a novel protective strategy for brain injuries and neurological disorders
WO2005115432A3 (fr) Traitement de maladies et de troubles oculaires utilisant des compositions lantibiotiques
WO2007087154A3 (fr) Méthodes destinées à renforcer les effets thérapeutiques d'une neurotoxine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09802740

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2010522632

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09802740

Country of ref document: EP

Kind code of ref document: A1